SELLAS receives Orphan Medicinal Product Designation for Galinpepimut-S
SELLAS Life Sciences announced the COMP of the EMA has approved orphan medicinal product designation or galinpepimut-S, the Company’s lead product candidate, for treatment of multiple myeloma. GPS is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 protein. September 13, 2018